DMAC Stock Summary and Trading Ideas (Diamedica Therapeutics | NASDAQ:DMAC)

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

Diamedica Therapeutics trades on the NASDAQ stock market under the symbol DMAC.

As of April 25, 2024, DMAC stock price climbed to $2.49 with 993 million shares trading.

DMAC has a beta of 1.68, meaning it tends to be more sensitive to market movements. DMAC has a correlation of 0.07 to the broad based SPY ETF.

DMAC has a market cap of $94.48 million. This is considered a Micro Cap stock.

In the last 3 years, DMAC stock traded as high as $9.94 and as low as $1.12.

The top ETF exchange traded funds that DMAC belongs to (by Net Assets): VTI, VXF, IWC, AVSC.

DMAC has outperformed the market in the last year with a return of +53.7%, while the SPY ETF gained +22.4%. However, in the most recent history, DMAC shares have underperformed the stock market with its stock returning -7.1% in the last 3 month period and -6.0% for the last 2 week period, while SPY has returned +3.0% and -3.1%, respectively.

DMAC support price is $2.33 and resistance is $2.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DMAC stock will trade within this expected range on the day.